Current File : //var/www/html/shaban/duassis/api/public/storage/xwqtu/cache/161874e7ed283e2888e101d1961afe1a
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:13996:"Biopharma, a podcast from Accenture. Pioneers in biopharma: Meet the leaders steering the industry on a path that celebrates and supports women 27 May 2021 Join us for this one-day virtual event to hear from three amazing thought leaders taking the biopharma industry to new heights. Biopharma Series A was stable in the first half, while overall investment is on pace for record dollars in 2020. We continued to see a significant number of large crossover-led mezzanine financings in Q1 and Q2 2020. COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks. Biopharma International 32(1):8-10. Jessica started her career in the pharmaceutical industry as a Statistical Programmer and Biostatistician after receiving a Master of Public Health in Epidemiology & Biostatistics at the George Washington University. Justyna is responsible for all medical isotope development and operations related to clinical and commercial programs. Our products are targeted radioligands, a technology that hold significant promise to treat cancer. POINT Biopharma is a globally focused radiopharmaceutical company with a growing portfolio of best in class radiopharmaceutical assets. Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. August 4, 2020 – TORONTO, Canada – POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands 2 as precision medicines for the treatment of cancer. The company's therapies combine with companion molecular imaging agents and PET or CT that kills cancer cells and leaves surrounding healthy cells untouched which is then mobilized to the site of disease, amplifying the therapeutic effect, enabling physicians to … Bioprocess development is often divided into upstream process development and downstream process development. TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) — POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round. form 8.3 irish takeover paneldisclosure under rule 8.3 of the irish takeover panel act, 1997, takeover rules, 2013dealings by persons with interests in relevant securities representing 1% or more 1. ... And while COVID-19 may at some point dwindle away, Dr. Parhami says MAX BioPharma is here to stay in Santa Monica. Uniting across biopharma sector But now there are also NIIMBL-led projects as well. BSV Series - Sampling Valves. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible … platform to discover and develop novel oral … Our website plays a crucial role in connecting us to our sponsors and volunteers, while also bringing internal news and industry updates at your fingertips. Justyna has expertise in working with a variety of medical isotopes, including sourcing, supply chain, development and manufacturing, and application to radiopharmaceutical manufacturing. Justyna has a MSc. in biochemistry from McMaster University. About POINT Biopharma POINT is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. Artificial develops software automation platform for biopharma labs. ... Landos was able to stretch its $10 million Series A round far. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT … He is president since 2005 of Newport Biotechnology Consultants and has written many articles for Genetic Engineering and Biotechnology News, Life Science Leader, and other Biotechnology journals. platform to discover and develop novel oral therapeutics for patients with autoimmune and inflammatory diseases, today announced the successful outcome of an End-of … The biopharma company, focused on topical drug development, is holding an invitation-only opening ceremony on … platform to discover and develop novel oral … Your host is Tom Lehman. About POINT Biopharma. POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. In a 13D filing on PDL BioPharma Inc. (NASDAQ:PDLI), Dan Loeb's Third Point LLC disclosed a 7.5% stake (8.6 million shares) in the company.This is … M12 will be represented by Kouki Harasaki and he will join Artificial’s Board of Directors. Creating Differences &. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T … New COVID-19 variants are making it harder to forecast the trajectory of the global pandemic, as well as the potential impact on vaccine developers’ stocks. I (Nasdaq: RACA) (“RACA”), a special purpose acquisition company, or SPAC, sponsored by RA … — I am a staff writer covering healthcare. POINT is … Verista, a leading consulting firm focused on compliance services primarily to the pharmaceutical and biotech industries, announced a collaborative partnership with INCOG BioPharma Services, a newly formed Contract Development and Manufacturing Organization (CDMO) also based in Fishers, Indiana. A double attack in chess is when you create multiple threats with one move. ... Landos was able to stretch its $10 million Series A round far. The successful close of POINT’s Series A further strengthens the Company’s position to become the global leader in radioligand treatments. Package labelling is also a ... biological risks is the ISO 10993 series of standard. And in that role, I have Six years ago, Gaurav Shah was working in the cell and gene therapy division of Novartis when an investor meeting changed his life. Start Listening It has become one of the fastest growing sectors in Bangladesh. POINT Biopharma is a globally focused radiopharmaceutical company with a growing portfolio of … At Novartis, Shah was shepherding along Kymriah, a blood cancer treatment that would later become the first CAR-T cell therapy approved in the U.S. POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Landos Biopharma "Let's say that I'm completely convinced that I have the cure for all cancers. POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients August 04, 2020 07:30 ET | Source: POINT Biopharma Two areas that must be streamlined are equipment cleaning and data validation. BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.) POINT is committed to novel treatments and continued innovation of radiopharmaceutical assets.” Joe McCann, POINT Biopharma CEO adds, “We are excited to … Define tomorrow. The biotech is looking to build a pipeline of ADCS around uPARAP, which plays a role in tumor infiltration and could offer a novel pathway to target hard-to-crack tumors. Prestige BioPharma strives to improve accessibility and affordability for existing biologic drugs and research on unmet medical needs to provide cure for devastating diseases. Microsoft’s M12 venture fund has participated in Artificial’s $21.5M Series A funding round. Through the partnership, Verista will provide comprehensive engineering, … 4. About POINT Biopharma. Female Leaders Series Ambition Nation Listed 50 - 2020/2021 Nurturing Ambition David Schenkein works in his office at Agios Pharmaceuticals Inc. The new facility will focus on producing and distributing more than 400,000 doses of radiogliands, the company's cancer treatments. Lead today. And it promises more jobs are on the horizon. INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu … Presently the industry meets 97% of local demand and exports to more than 80 countries. Pathfinders in Biopharma Perspectives from the cutting edge of biotech and pharma. In today's challenging HCP engagement and healthcare marketing/sales environment, field teams are searching for that double, triple, quadruple attack to win in their arena. This mezzanine activity exceeds 2019’s pace and … 08:30-14:30 Fridays We continued to see a significant number of large crossover-led mezzanine financings in Q1 and Q2 2020. At no point in the modern era have the health and resilience of the biopharma industry been more crucial. Biopharma Stock On Our Long Disclosures List Continues To Intrigue Us We’d like to once again point you to a video conversation we had with the CEO of a biopharma company seemingly on the cusp of making some major FDA trial breakthroughs in the treatment of certain kinds of cancers. The IBSC is one of the key statutory bodies operating directly from the premises of the institution and is responsible for proper implementation of biosafety, rules, regulations, and guidelines. IBSC is the nodal point for implementation of the biosafety guidelines in an institution. Dr. Michael Rome joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Clinical stage Global pharmaceutical company focused on the development and commercialization of radiotherapeutic products A quick read of whose wallets got thicker in the biopharma industry, from largest to smallest. Thanks to the boom in special-purpose acquisition companies – or Spacs – the Canadian company looks set to reach that goal several months sooner than planned. TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radiopharmaceutical drug development and commercialization. The compound was developed by Bioprojet, a Paris, France-based pharmaceutical company established in 1982. Our company is growing rapidly: we just announced a phase 3 clinical trial for our novel radioligand based prostate cancer treatment, established our U.S. manufacturing center in Indianapolis, and have a pipeline of next generation oncology products in development. International business activities at Biopharma Limited. Confirming Identity 4 Confirming Identity Here are the high-level steps and products needed to create and match sequences. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T … UK-based Avacta Group has entered into a license agreement with Canadian firm POINT Biopharma to provide…. Our office hours are: 08:30-17:00 Monday to Thursday. On a per-share basis, the Seattle-based company said … The company was established in 2019 and plans to begin clinical trial programs this year. BNW Series - Weir Diaphragm Valves. Point Biopharma trotted out to near-unicorn status in March as part of a reverse merger with a SPAC backed by RA Capital's Peter Kolchinsky to … The Biopharma M&A Suite is a series of tools that clients can use to identify potential products or technologies that could be a good match for their current or future portfolio and capabilities. Improving cancer outcomes with Radioligand Therapies. “As we grew, it became apparent that we needed a strategic plan around our higher-level goals,” Lee said, “We needed to talk to end-users about their five-year vision, about where they expected biopharmaceuticals manufacturing to be in five years.” New startup biotech Oyster Point Pharmaceuticals came out of stealth today with $22 million led by venture capital firms New Enterprise Associates (NEA) and Versant Ventures. CTI BioPharma Corp. (CTIC) on Tuesday reported a loss of $17.3 million in its first quarter. POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of … To date, Xeris Biopharma Holdings has not conducted any activities other than those incidental to its formation and the execution of the Transaction Agreement. Pitolisant specifically targets the histamine-3 (H3) receptor. BTV Series - Tank Outlet Valves. K.John Morrow, PhD , is a long-time collaborator with BioPlan Associates, Inc. Point Biopharma General Information Description. TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round. POINT Biopharma has a strong pipeline of exciting radiopharmaceutical treatments for a variety of cancer indications. Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. ";s:7:"keyword";s:24:"point biopharma series a";s:5:"links";s:561:"<a href="https://api.duassis.com/storage/xwqtu/please-find-the-attached-file">Please Find The Attached File</a>,
<a href="https://api.duassis.com/storage/xwqtu/maybelline-sky-high-mascara-target">Maybelline Sky High Mascara Target</a>,
<a href="https://api.duassis.com/storage/xwqtu/norwood%2C-massachusetts-county">Norwood, Massachusetts County</a>,
<a href="https://api.duassis.com/storage/xwqtu/ashthorpe-premium-drum-set">Ashthorpe Premium Drum Set</a>,
<a href="https://api.duassis.com/storage/xwqtu/dollar-general-horn-lake">Dollar General Horn Lake</a>,
";s:7:"expired";i:-1;}
Mini Shell